Mingfei Li1,2, Ying Wang2, Ndindam Ndiwane1, Michelle B Orner1, Natalia Palacios3,4, Brant Mittler5, Dan Berlowitz3, Lewis E Kazis1,6, Weiming Xia4,7. 1. Center for Healthcare Organization and Implementation Research (CHOIR), Bedford VA Healthcare System, Bedford, Massachusetts, United States of America. 2. Department of Mathematical Sciences, Bentley University, Waltham, Massachusetts, United States of America. 3. Department of Public Health, Zuckerberg College of Health Sciences, University of Massachusetts Lowell, Lowell, Massachusetts, United States of America. 4. Geriatric Research Education Clinical Center, Bedford VA Healthcare System, Bedford, Massachusetts, United States of America. 5. Department of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America. 6. Department of Health Law, Policy and Management, Boston University School of Public Health, Boston, Massachusetts, United States of America. 7. Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts, United States of America.
Abstract
BACKGROUND: A number of studies have reported the association between the use of angiotensin-converting enzyme inhibitor (ACEI) and angiotensin-II receptor blocker (ARB) medications and the occurrence or severity of coronavirus disease 2019 (COVID-19). Published results are inconclusive, possibly due to differences in participant comorbidities and sociodemographic backgrounds. Since ACEI and ARB are frequently used anti-hypertension medications, we aim to determine whether the use of ACEI and ARB is associated with the occurrence and severity of COVID-19 in a large study of US Veterans with hypertension. METHODS: Data were collected from the Department of Veterans Affairs (VA) National Corporate Data Warehouse (VA-COVID-19 Shared Data Resource) between February 28, 2020 and August 18, 2020. Using data from 228,722 Veterans with a history of hypertension who received COVID-19 testing at the VA, we investigated whether the use of ACEI or ARB over the two years prior to the index date was associated with increased odds of (1) a positive COVID-19 test, and (2) a severe outcome (hospitalization, mortality, and use of intensive care unit (ICU) and/or mechanical ventilation) among COVID-19-positive patients. We used logistic regression with and without propensity score weighting (PSW) to estimate the odds ratio (OR) and 95% confidence interval (95% CI) for the association between ACEI/ARB use and a positive COVID-19 test result. The association between medication use and COVID-19 outcome severity was examined using multinomial logistic regression comparing participants who were not hospitalized to participants who were hospitalized, were admitted to the ICU, used a mechanical ventilator, or died. All models were adjusted for relevant covariates, including demographics (age, sex, race, ethnicity), selected comorbidities, and the Charlson Comorbidity Index (CCI). RESULTS: The use of ACEI significantly decreased the odds of a positive COVID-19 test among Veterans with hypertension (OR = 0.917, (0.887, 0.948) and OR = 0.926, (0.894, 0.958) with PSW). The use of ACEI, but not of ARB, was also associated with significantly increased odds of using mechanical ventilators (OR = 1.265, (1.010, 1.584) and OR = 1.210, (1.053, 1.39) with PSW) among all COVID-19 inpatients compared to outpatients. CONCLUSIONS: In this study of Veterans with hypertension, ACEI was significantly associated with decreased odds of testing positive for COVID-19. With the exception of the association of ACEI with a small non-clinically-important increase in the odds of using mechanical ventilators, neither ACEI nor ARB was found to be associated with clinical severity or mortality among COVID-19-positive Veterans. The results of this study need further corroboration and validation in other cohort samples outside the VA.
BACKGROUND: A number of studies have reported the association between the use of angiotensin-converting enzyme inhibitor (ACEI) and angiotensin-II receptor blocker (ARB) medications and the occurrence or severity of coronavirus disease 2019 (COVID-19). Published results are inconclusive, possibly due to differences in participant comorbidities and sociodemographic backgrounds. Since ACEI and ARB are frequently used anti-hypertension medications, we aim to determine whether the use of ACEI and ARB is associated with the occurrence and severity of COVID-19 in a large study of US Veterans with hypertension. METHODS: Data were collected from the Department of Veterans Affairs (VA) National Corporate Data Warehouse (VA-COVID-19 Shared Data Resource) between February 28, 2020 and August 18, 2020. Using data from 228,722 Veterans with a history of hypertension who received COVID-19 testing at the VA, we investigated whether the use of ACEI or ARB over the two years prior to the index date was associated with increased odds of (1) a positive COVID-19 test, and (2) a severe outcome (hospitalization, mortality, and use of intensive care unit (ICU) and/or mechanical ventilation) among COVID-19-positive patients. We used logistic regression with and without propensity score weighting (PSW) to estimate the odds ratio (OR) and 95% confidence interval (95% CI) for the association between ACEI/ARB use and a positive COVID-19 test result. The association between medication use and COVID-19 outcome severity was examined using multinomial logistic regression comparing participants who were not hospitalized to participants who were hospitalized, were admitted to the ICU, used a mechanical ventilator, or died. All models were adjusted for relevant covariates, including demographics (age, sex, race, ethnicity), selected comorbidities, and the Charlson Comorbidity Index (CCI). RESULTS: The use of ACEI significantly decreased the odds of a positive COVID-19 test among Veterans with hypertension (OR = 0.917, (0.887, 0.948) and OR = 0.926, (0.894, 0.958) with PSW). The use of ACEI, but not of ARB, was also associated with significantly increased odds of using mechanical ventilators (OR = 1.265, (1.010, 1.584) and OR = 1.210, (1.053, 1.39) with PSW) among all COVID-19 inpatients compared to outpatients. CONCLUSIONS: In this study of Veterans with hypertension, ACEI was significantly associated with decreased odds of testing positive for COVID-19. With the exception of the association of ACEI with a small non-clinically-important increase in the odds of using mechanical ventilators, neither ACEI nor ARB was found to be associated with clinical severity or mortality among COVID-19-positive Veterans. The results of this study need further corroboration and validation in other cohort samples outside the VA.
Authors: Hakeam A Hakeam; Muhannad Alsemari; Zainab Al Duhailib; Leen Ghonem; Saad A Alharbi; Eid Almutairy; Nader M Bin Sheraim; Meshal Alsalhi; Ali Alhijji; Sara AlQahtani; Mohammed Khalid; Mazin Barry Journal: J Cardiovasc Pharmacol Ther Date: 2020-11-24 Impact factor: 2.457
Authors: Sascha Dublin; Rod L Walker; James S Floyd; Susan M Shortreed; Sharon Fuller; Ladia Albertson-Junkans; Laura B Harrington; Mikael Anne Greenwood-Hickman; Beverly B Green; Bruce M Psaty Journal: Am J Hypertens Date: 2021-04-20 Impact factor: 3.080
Authors: Ivan T Lee; Tsuguhisa Nakayama; Chien-Ting Wu; Yury Goltsev; Sizun Jiang; Phillip A Gall; Chun-Kang Liao; Liang-Chun Shih; Christian M Schürch; David R McIlwain; Pauline Chu; Nicole A Borchard; David Zarabanda; Sachi S Dholakia; Angela Yang; Dayoung Kim; Han Chen; Tomoharu Kanie; Chia-Der Lin; Ming-Hsui Tsai; Katie M Phillips; Raymond Kim; Jonathan B Overdevest; Matthew A Tyler; Carol H Yan; Chih-Feng Lin; Yi-Tsen Lin; Da-Tian Bau; Gregory J Tsay; Zara M Patel; Yung-An Tsou; Alexandar Tzankov; Matthias S Matter; Chih-Jaan Tai; Te-Huei Yeh; Peter H Hwang; Garry P Nolan; Jayakar V Nayak; Peter K Jackson Journal: Nat Commun Date: 2020-10-28 Impact factor: 14.919
Authors: Ann Z Bauer; Rebecca Gore; Susan R Sama; Richard Rosiello; Lawrence Garber; Devi Sundaresan; Anne McDonald; Patricia Arruda; David Kriebel Journal: J Clin Hypertens (Greenwich) Date: 2020-11-21 Impact factor: 3.738
Authors: Shelly Karuna; Shuying Sue Li; Shannon Grant; Stephen R Walsh; Ian Frank; Martin Casapia; Meg Trahey; Ollivier Hyrien; Leigh Fisher; Maurine D Miner; April K Randhawa; Laura Polakowski; James G Kublin; Lawrence Corey; David Montefiori Journal: PLoS Med Date: 2021-12-06 Impact factor: 11.613